A hybrid protocol for peptide development: integrating deep generative models and physics simulations for biomolecular design targeting IL23R/IL23.

Journal: International journal of biological macromolecules
Published Date:

Abstract

Recent advances in machine learning have revolutionized molecular design; however, a gap remains in integrating generative models with physics-based simulations to develop functional modulators, such as stable peptides, for challenging targets like the interleukin-23 receptor (IL23R) and its associated cytokine, interleukin-23 (IL23). The IL23R/IL23 axis plays a critical role in autoimmune diseases, and current therapies have largely been limited to antibody-based approaches. To address this gap, we employed a hybrid computational approach that combines Long Short-Term Memory (LSTM) networks for peptide generation, a Gated Recurrent Unit (GRU)-based classifier for anti-inflammatory property prediction, and molecular dynamics (MD) simulations to assess structural dynamics, binding interactions, as well as key properties such as binding affinity and stability. Using this hybrid framework, we identified novel inhibitory peptides, particularly P4, with an IC of 2 μM. Systematic experimental validation established its inhibitory activity, elucidated its binding mechanism, confirmed its specificity toward the IL23R, and demonstrated its ability to disrupt IL23R/IL23 interaction. This integrated approach highlights the significant potential of combining deep learning and simulations to accelerate the identification of peptide-based therapeutics targeting key protein targets.

Authors

  • Naila Qayyum
    Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea. Electronic address: nailaqayyum16@ajou.ac.kr.
  • Hana Seo
    Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea.
  • Noman Khan
    Sejong University, Seoul, Republic of Korea.
  • Abdul Manan
    Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
  • Rajath Ramachandran
    Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea.
  • Muhammad Haseeb
    S&K Therapeutics, Ajou University Campus Plaza 418, 199 Worldcup-ro, Yeongtong-gu, Suwon 16502, Republic of Korea.
  • Eunha Kim
    Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
  • Sangdun Choi
    Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea. sangdunchoi@ajou.ac.kr.